These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 10447443)

  • 21. Duration of anticoagulation after first episode of unprovoked venous thromboembolism.
    Abdel-Razeq HN; Radwi GR
    Saudi Med J; 2004 Nov; 25(11):1776; author reply 1776-7. PubMed ID: 15573235
    [No Abstract]   [Full Text] [Related]  

  • 22. Low-intensity versus conventional-intensity warfarin for prevention of recurrent venous thromboembolism.
    Huisman MV; van der Meer FJ; van Rooden CJ; Prins MH
    N Engl J Med; 2003 Nov; 349(22):2164-7; author reply 2164-7. PubMed ID: 14645647
    [No Abstract]   [Full Text] [Related]  

  • 23. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism.
    Veeger NJ; Piersma-Wichers M; Tijssen JG; Hillege HL; van der Meer J
    Br J Haematol; 2005 Feb; 128(4):513-9. PubMed ID: 15686461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-intensity versus conventional-intensity warfarin for prevention of recurrent venous thromboembolism.
    Tran HA
    N Engl J Med; 2003 Nov; 349(22):2164-7; author reply 2164-7. PubMed ID: 14658126
    [No Abstract]   [Full Text] [Related]  

  • 25. [Clexane in prevention of acute venous thrombosis and pulmonary thromboembolism].
    Kirienko AI; Zolotukhin IA
    Ter Arkh; 1998; 70(11):78-80. PubMed ID: 9949471
    [No Abstract]   [Full Text] [Related]  

  • 26. Venous thromboembolism: risk factors for recurrence.
    Zhu T; Martinez I; Emmerich J
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):298-310. PubMed ID: 19228602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mars or venus--is sex a risk factor for recurrent venous thromboembolism?
    Elliott CG; Rubin LJ
    N Engl J Med; 2004 Jun; 350(25):2614-6. PubMed ID: 15201419
    [No Abstract]   [Full Text] [Related]  

  • 28. Extended prophylaxis of venous thromboembolism with idraparinux.
    ; Buller HR; Cohen AT; Davidson B; Decousus H; Gallus AS; Gent M; Pillion G; Piovella F; Prins MH; Raskob GE
    N Engl J Med; 2007 Sep; 357(11):1105-12. PubMed ID: 17855671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insufficient evidence supporting low-intensity warfarin for venous thromboembolism (VTE) prophylaxis.
    Cundiff DK
    MedGenMed; 2003 Jul; 5(3):2. PubMed ID: 14600639
    [No Abstract]   [Full Text] [Related]  

  • 30. [Prevention of venous thromboembolism in orthopedic surgery and traumatology].
    Agnelli G; Cimminiello C
    Recenti Prog Med; 2007 Jan; 98 Suppl 1():25S-32S. PubMed ID: 17455706
    [No Abstract]   [Full Text] [Related]  

  • 31. Oral anticoagulation strategies after a first idiopathic venous thromboembolic event.
    Aujesky D; Smith KJ; Roberts MS
    Am J Med; 2005 Jun; 118(6):625-35. PubMed ID: 15922694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [There is evidence for prolonged low-intensity warfarin therapy after venous thrombosis].
    Schulman S
    Lakartidningen; 2003 Jun; 100(24):2118-21. PubMed ID: 12841107
    [No Abstract]   [Full Text] [Related]  

  • 33. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia.
    Palareti G; Legnani C; Cosmi B; Valdré L; Lunghi B; Bernardi F; Coccheri S
    Circulation; 2003 Jul; 108(3):313-8. PubMed ID: 12847064
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A synthetic pentasaccharide for the prevention of deep-vein thrombosis.
    Hull R; Pineo G
    N Engl J Med; 2001 Jul; 345(4):291; author reply 292. PubMed ID: 11474672
    [No Abstract]   [Full Text] [Related]  

  • 35. Differences in the safety profiles of two low-molecular-weight heparins.
    Ofosu FA
    Thromb Haemost; 2008 Jun; 99(6):989-90. PubMed ID: 18521496
    [No Abstract]   [Full Text] [Related]  

  • 36. Idiopathic venous thrombosis. Long-term anticoagulant therapy? No.
    Kyrle PA
    Hamostaseologie; 2006 Jan; 26(1):52-4. PubMed ID: 16444323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Perioperative bridging with fondaparinux in a woman with antithrombin deficiency.
    Bauersachs R; Alban S
    Thromb Haemost; 2007 Mar; 97(3):498-9. PubMed ID: 17334522
    [No Abstract]   [Full Text] [Related]  

  • 38. [Thrombophilic disorders in venous thromboembolism. The clinical perspective].
    Schmidt B; Schellong S
    Med Klin (Munich); 2003 Mar; 98(3):133-9. PubMed ID: 12647087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Long-term prophylaxis after venous thromboembolism].
    Gøtze JP; Friis-Hansen LJ; Thorsen S; Rehfeld JF
    Ugeskr Laeger; 2003 Jul; 165(29):2896-7. PubMed ID: 12908362
    [No Abstract]   [Full Text] [Related]  

  • 40. Prevention of recurrent idiopathic venous thromboembolism.
    Goldhaber SZ
    Circulation; 2004 Dec; 110(24 Suppl 1):IV20-4. PubMed ID: 15598644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.